- medical research
Alphyn Biologics Announces Enrollment Passes Halfway Point in Phase2a Clinical Trial of Mild-to-Moderate Atopic Dermatitis Treatment
ANNAPOLIS, Md., Oct. 18, 2022 /PRNewswire/ -- Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced today that enrollment in its Phase2a clinical trial of AB-101a for mild-to-moderate atopic dermatitis (AD) has passed the halfway point. The randomized, vehicle-controlled, double-blind trial is evaluating AB-101a for the treatment of AD in adults and children, starting at age 2...
Read more